Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$17.98 USD

17.98
582,160

-0.65 (-3.49%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $17.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform

Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) on improvement in testing volume across all its businesses.

Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk

Myriad Genetics (MYGN) announces collaboration with Onsite Women's Health to develop a breast cancer risk assessment program.

Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test

Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.

Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod

Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.

Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement

Myriad Genetics' (MYGN) GeneSight report will contain details on how a patient's smoking history may affect their metabolism of certain medications.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss

Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance.

Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Myriad (MYGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 20% and 1.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe

Myriad Genetics' (MYGN) collaboration with medical imaging provider, SimonMeD, is expected to advance precision medicine with a new hereditary cancer assessment program.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.

Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform

Myriad Genetics (MYGN) announces research collaboration with MD Anderson on metastatic RCC with its high-definition MRD research testing platform based on whole-genome sequencing.

Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio

Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.

Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View

Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.

Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of -10.53% and 5.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will CytomX Therapeutics (CTMX) Report Negative Q1 Earnings? What You Should Know

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing

Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.

Myriad Genetics' (MYGN) New Pact to Boost Precision Medicine

Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.

Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access

Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.

Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls

Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.

Myriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind

Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.

Halozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.